We are monitoring the impact of COVID-19 on North America Cancer Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 159
Share on
Share on

North America Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, Type, Conjugated Cancer Therapies & Country (The United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 159
Pages: 132

North America Cancer Monoclonal Antibodies Market Size (2021 to 2026)

The size of the Cancer Monoclonal Antibodies Market in North America was worth USD 10.64 billion in 2021. This value is further expected to grow and worth USD 17.53 billion by the end of 2026, registering a CAGR of 10.5% from 2021 to 2026.

The market is mainly driven by the increasing number of patients suffering from different types of cancer. Growing demand to improve the quality of treatment procedures is surging the growth rate of the market. The rise in the revenue in both developed and developing countries are greatly influencing the demand for the cancer monoclonal antibodies market in North America. Growing support from the government and non-government organizations through investments in the construction o hospitals is propelling this market's demand. Also, increasing the scale of hospitals with the latest equipment is leveraging the growth of the market. 

Growing popularity in manufacturing new products with the latest technology is creating growth opportunities for the market. Increasing prevalence to promote the wellbeing of the patient after treatment is also likely to outshine the market demand. Escalating healthcare expenditure, especially in urban areas, is boosting up the growth rate of North American cancer monoclonal antibodies. 

However, lack of proper knowledge over the availability of different treatment procedures due to less training programs is slightly restricting the demand of the market. Fluctuations in the availability of raw materials are hindering the growth rate of this market in North America. Rapid changes in economic strategies are also impacting negatively on the growth of the cancer monoclonal antibodies market. Increasing prices of final products remain a challenging factor for the market. 

This research report on the North America Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:

By Application: 

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkin’s And Non-Hodgkin’s Lymphoma
  • Colorectal
  • Leukemia
  • Others

By Type: 

  • Murine Antibodies
  • Chimeric & Humanised Antibodies
  • Fully Humanized Antibodies

By Conjugated Cancer Therapies: 

  • Immunoliposome
  • Radioimmunotherapy
  • ADEPT
  • Immunocytokines
  • Others

By Country: 

  • The United States
  • Canada
  • Rest of North America

Regionally, North America is holding with the highest shares of the market, and the USA is the one ruling with dominant shares of the market in this region. Rising capital income is one of the most common factors propelling the growth of the market. Canada and Mexico are next to the USA in leading dominant shares of the market. Increasing investments in the development of new techniques in cancer treatment procedures elevates the growth rate of the cancer monoclonal antibodies market in North America. 

Promising companies operating in the North American Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis, and Spectrum Pharmaceuticals.           

  1. Introduction

                1.1 Market Definition                                                                                    

                1.2 Study Deliverables                                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                                          

                1.4 General Study Assumptions                                                                                

  1. Research Methodology

                2.1 Introduction                                                                                               

                2.2 Research Phases                                                                                      

                                2.2.1 Secondary Research                                                                           

                                2.2.2 Primary Research                                                                 

                                2.2.3 Econometric Modelling                                                                      

                                2.2.4 Expert Validation                                                                  

                2.3 Analysis Design                                                                                         

                2.4 Study Timeline                                                                                          

  1. Overview

                3.1 Executive Summary                                                                                

                3.2 Key Inferences                                                                                         

                3.3 New Developments                                                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                                                          

                4.2 Market Restraints                                                                                    

                4.3 Key Challenges                                                                                         

                4.4 Current Opportunities in the Market                                                                                              

  1. Market Segmentation

                5.1 By Application                                                                                           

                                5.1.1 Liver                                                                           

                                5.1.2 Breast                                                                       

                                5.1.3 Brain                                                                          

                                5.1.4 Blood                                                                         

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma                                                                    

                                5.1.6 Colorectal                                                                

                                5.1.7 Leukaemia                                                                              

                                5.1.8 Others                                                                      

                5.2 By Type                                                                                        

                                5.2.1 Murine Antibodies                                                                              

                                5.2.2 Chimeric and Humanised Antibodies                                                                           

                                5.2.3 Fully Humanized Antibodies                                                                            

                5.3 Conjugate Cancer Therapies                                                                                               

                                5.3.1 Immunoliposome                                                                

                                5.3.2 Radioimmunotherapy                                                                        

                                5.3.3 ADEPT                                                                       

                                5.3.4 Immunocytokines                                                                

                                5.3.5 Others                                                                      

  1. Geographical Analysis

                6.1 Introduction                                                                                               

                6.2 United States                                                                                            

                6.3 Canada                                                                                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                                                                         

                                7.1.1 Political                                                                     

                                7.1.2 Economic                                                                 

                                7.1.3 Social                                                                         

                                7.1.4 Technological                                                                         

                                7.1.5 Legal                                                                          

                                7.1.6 Environmental                                                                       

                7.2 Porter’s Five analysis                                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                                        

                                7.2.2 Bargaining Power of Consumers                                                                    

                                7.2.3 Threat of New Entrants                                                                     

                                7.2.4 Threat of Substitute Products and Services                                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                                     

  1. Market Leaders' Analysis

                8.1 Roche                                                                           

                                8.1.1 Overview                                                                 

                                8.1.2 Product Analysis                                                                   

                                8.1.3 Strategic Evaluation and Operations                                                                            

                                8.1.4 Financial analysis                                                                  

                                8.1.5 Legal issues                                                                             

                                8.1.6 Recent Developments                                                                       

                                8.1.7 SWOT analysis                                                                       

                                8.1.8 Analyst View                                                                          

                8.2 Amgen                                                                         

                8.3 Genmab                                                                      

                8.4 Glaxosmithkline                                                                       

                8.5 Bristol Meyer Squibb                                                                              

                8.6 Eli Lilly                                                                           

                8.7 Immunogen                                                                               

                8.8 Novartis                                                                       

                8.9 Seattle Genetics                                                                       

                8.10 Spectrum Pharmaceuticals                                                                

  1. Competitive Landscape

                9.1 Market share analysis                                                                                            

                9.2 Merger and Acquisition Analysis                                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                                         

                9.4 New Product Launches                                                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                                                     

                10.2 Investment Opportunities                                                                                 

     Appendix                                                                                                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Billion)
  3. North America Liver Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Breast Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Brain Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Blood Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Leukaemia Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Billion)
  12. North America Murine Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  15. North America Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Billion)
  16. North America Immunoliposome Market, By Region, From 2021 to 2026 (USD Billion)
  17. North America Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  18. North America ADEPT Market, By Region, From 2021 to 2026 (USD Billion)
  19. North America Immunocytokines Market, By Region, From 2021 to 2026 (USD Billion)
  20. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  21. United States Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Billion)
  22. Canada Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Billion)
  23. United States Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Billion)
  24. United States Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Billion)
  25. United States Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Billion)
  26. Canada Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Billion)
  27. Canada Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Billion)
  28. Canada Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample